Company news

Ardelyx, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 19, 2025

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

February 18, 2025

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

January 29, 2025

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

January 12, 2025

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

November 19, 2024

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

November 7, 2024

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

November 4, 2024

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

October 30, 2024

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting

October 27, 2024

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

October 23, 2024

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

October 21, 2024

Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community

October 20, 2024

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

October 16, 2024

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week

October 14, 2024

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

October 8, 2024

Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference

September 4, 2024

Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

August 7, 2024

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

July 31, 2024

Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion

July 30, 2024

Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

July 17, 2024

Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines

July 16, 2024

To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA

July 1, 2024

Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines

June 27, 2024

Ardelyx, Inc. Reports Employment Inducement Grants

May 29, 2024

Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

May 21, 2024

Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

May 20, 2024

Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)

May 15, 2024

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference

May 6, 2024

Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings

April 30, 2024

Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024

April 17, 2024

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

March 24, 2024

Ardelyx to Participate at the Cowen 44th Annual Health Care Conference

February 26, 2024

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 21, 2024

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

January 31, 2024

Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

January 7, 2024

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

January 2, 2024

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

November 14, 2023

Ardelyx Announces Departure of Board Member

November 12, 2023

Ardelyx to Participate at the Jefferies London Healthcare Conference

November 9, 2023

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

November 5, 2023

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

November 2, 2023

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

October 30, 2023

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

October 22, 2023

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

October 17, 2023

FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

October 16, 2023

Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital

October 16, 2023

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

October 12, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.